- Dasatinib as first line therapy in chronic myeloid leukaemia2011 | Faculty of Medicine in Hradec Králové
- Comments to the study Dasatinib 140 mg once daily vs dasatinib 70 mg bid in patients with CML in accelerated phase +12009 | Publication without faculty affiliation
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | First Faculty of Medicine
- Detection of dasatinib using pre-reaction with copper and mass spectrometry2015 | Faculty of Physical Education and Sport
- Dasatinib - účinná léčba chronické myeloidní leukemie a plánované těhotenství2017 | First Faculty of Medicine
- Pharmacokinetics of Dasatinib2019 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment CA180399Publication without faculty affiliation
- Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans2023 | First Faculty of Medicine
- The requirements for dasatinib sensitivity in human melanoma cell lines2014 | First Faculty of Medicine
- Current approach for chronic myeloid leukemia treatment with tyrosin kinase inhibitors2016 | First Faculty of Medicine
- Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice2021 | Publication without faculty affiliation
- Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis2017 | Faculty of Science
- Commentary to the study +12009 | Faculty of Medicine in Hradec Králové
- Drug Induced Pulmonary Arterial Hypertension2018 | First Faculty of Medicine
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
- Termination of the treatment in chronic myeloid leukemia - possi bility of stopping the tyrosine kinase inhibitors2017 | First Faculty of Medicine
- Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery2009 | First Faculty of Medicine
- Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin2014 | Faculty of Science
- BCR-ABL mutation analysis allows to provide "tailors therapy" for CML patients resistant to imatinib2010 | Faculty of Medicine in Hradec Králové
- Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials2013 | Publication without faculty affiliation
- Significance of thyrosinkinase inhibitors before and after stem cell transplantation in patients with Ph+ acute lymphoblastic leukemia2010 | Faculty of Medicine in Hradec Králové
- Drug-induced pericarditis2022 | Publication without faculty affiliation
- Interferon-alpha Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients2016 | First Faculty of Medicine, Faculty of Science, Third Faculty of Medicine
- Treatment of chronic myeloid leukemia in adults in 20102010 | Faculty of Medicine in Hradec Králové
- Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase2006 | First Faculty of Medicine
- Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib2017 | Publication without faculty affiliation
- ABL1, SRC and other non-receptor tyrosine-kinases as new targets for specific anticancer therapy2010 | First Faculty of Medicine